TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET. The event will provide an in-depth review of the poster presented at the ASH Annual Meeting, including two-year relapse data on initial patients from TScan’s ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The Company will discuss its improved commercial-ready manufacturing pr
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
- TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswire
TCRX
Earnings
- 8/12/25 - In-Line
TCRX
Sec Filings
- 11/26/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- TCRX's page on the SEC website